2552 — Hua Medicine Share News
0.000.00%
Last trade - 00:00- HK$2.25bn
- HK$1.40bn
- CNY492.93m
Brief: Hua Medicine Posts Profit For The Year RMB1.11 Billion
Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
Brief: Hua Medicine Posts H1 Revenue Of RMB 217.4 Million
Brief: Hua Medicine Expects RMB1,184.1 Million Profit For HY
Brief: Hua Medicine Says IND Application Accepted By U.S. FDA
Brief: Hua Medicine Posts Total Revenue For Six Months RMB70.3 Million
Brief: Hua Medicine Entered Sales And Distribution Framework Agreement With 111, Inc.
Brief: Hua Medicine Posts FY Total Comprehensive Expense Of RMB203.4 Mln
Brief: Hua Medicine Says Unit To Acquire 100% Stake In Nanjing Ascendrare Pharmaceutical Technology
Brief: Hua Medicine Says FY Loss Before Tax Decreased 17% To RMB325.7 Million
Brief: WuXi AppTec's Long Position In Hua Medicine Falls To 6.99% - HKEX Filing
Brief: Hua Medicine Says HY Loss RMB165.3 Mln
Brief: Hua Medicine Posts FY Loss Attributable RMB393.6 Million
Brief: Hua Medicine Says Unit Enters Collaboration Agreement With Bayer Healthcare
Brief: Hua Medicine Posts HY Loss Before Tax Of About Rmb173.5 Million
Brief: Hua Medicine Says Dorzagliatin's Phase III Metformin Combination Trial Met Primary Efficacy And Safety End Point
HK-listed Hua Medicine hits 7-mth high on progress of therapy for diabetes
HK-listed Hua Medicine hits 4-week high on progress of diabetes therapy
Brief: Hua Medicine Announces Positive Results Of Combination Study Of Dorzagliatin With Empagliflozin (A Sglt-2 Inhibitor)